Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients
(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates the respiratory epithelium through angiotensin-converting enzyme-2 (ACE2) binding. Myocardial and endothelial expression of ACE2 could account for the growing body of reported evidence of myocardial injury in sev...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/12/4078 |
id |
doaj-105baddc94ff409983f51004c719e780 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena-Mihaela Cordeanu Nicolas Duthil Francois Severac Hélène Lambach Jonathan Tousch Lucas Jambert Corina Mirea Alexandre Delatte Waël Younes Anne-Sophie Frantz Hamid Merdji Valérie Schini-Kerth Pascal Bilbault Patrick Ohlmann Emmanuel Andres Dominique Stephan |
spellingShingle |
Elena-Mihaela Cordeanu Nicolas Duthil Francois Severac Hélène Lambach Jonathan Tousch Lucas Jambert Corina Mirea Alexandre Delatte Waël Younes Anne-Sophie Frantz Hamid Merdji Valérie Schini-Kerth Pascal Bilbault Patrick Ohlmann Emmanuel Andres Dominique Stephan Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients Journal of Clinical Medicine COVID-19 troponin myocardial injury SARS-CoV-2 cardiovascular biomarker |
author_facet |
Elena-Mihaela Cordeanu Nicolas Duthil Francois Severac Hélène Lambach Jonathan Tousch Lucas Jambert Corina Mirea Alexandre Delatte Waël Younes Anne-Sophie Frantz Hamid Merdji Valérie Schini-Kerth Pascal Bilbault Patrick Ohlmann Emmanuel Andres Dominique Stephan |
author_sort |
Elena-Mihaela Cordeanu |
title |
Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients |
title_short |
Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients |
title_full |
Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients |
title_fullStr |
Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients |
title_full_unstemmed |
Prognostic Value of Troponin Elevation in COVID-19 Hospitalized Patients |
title_sort |
prognostic value of troponin elevation in covid-19 hospitalized patients |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2020-12-01 |
description |
(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates the respiratory epithelium through angiotensin-converting enzyme-2 (ACE2) binding. Myocardial and endothelial expression of ACE2 could account for the growing body of reported evidence of myocardial injury in severe forms of Human Coronavirus Disease 2019 (COVID-19). We aimed to provide insight into the impact of troponin (hsTnI) elevation on SARS-CoV-2 outcomes in patients hospitalized for COVID-19. (2) Methods: This was a retrospective analysis of hospitalized adult patients with the SARS-CoV-2 infection admitted to a university hospital in France. The observation period ended at hospital discharge. (3) Results: During the study period, 772 adult, symptomatic COVID-19 patients were hospitalized for more than 24 h in our institution, of whom 375 had a hsTnI measurement and were included in this analysis. The median age was 66 (55–74) years, and there were 67% of men. Overall, 205 (55%) patients were placed under mechanical ventilation and 90 (24%) died. A rise in hsTnI was noted in 34% of the cohort, whereas only three patients had acute coronary syndrome (ACS) and one case of myocarditis. Death occurred more frequently in patients with hsTnI elevation (HR 3.95, 95% CI 2.69–5.71). In the multivariate regression model, a rise in hsTnI was independently associated with mortality (OR 3.12, 95% CI 1.49–6.65) as well as age ≥ 65 years old (OR 3.17, 95% CI 1.45–7.18) and CRP ≥ 100 mg/L (OR 3.62, 95% CI 1.12–13.98). After performing a sensitivity analysis for the missing values of hsTnI, troponin elevation remained independently and significantly associated with death (OR 3.84, 95% CI 1.78–8.28). (4) Conclusion: Our study showed a four-fold increased risk of death in the case of a rise in hsTnI, underlining the prognostic value of troponin assessment in the COVID-19 context. |
topic |
COVID-19 troponin myocardial injury SARS-CoV-2 cardiovascular biomarker |
url |
https://www.mdpi.com/2077-0383/9/12/4078 |
work_keys_str_mv |
AT elenamihaelacordeanu prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT nicolasduthil prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT francoisseverac prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT helenelambach prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT jonathantousch prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT lucasjambert prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT corinamirea prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT alexandredelatte prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT waelyounes prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT annesophiefrantz prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT hamidmerdji prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT valerieschinikerth prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT pascalbilbault prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT patrickohlmann prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT emmanuelandres prognosticvalueoftroponinelevationincovid19hospitalizedpatients AT dominiquestephan prognosticvalueoftroponinelevationincovid19hospitalizedpatients |
_version_ |
1724378838150938624 |
spelling |
doaj-105baddc94ff409983f51004c719e7802020-12-18T00:03:23ZengMDPI AGJournal of Clinical Medicine2077-03832020-12-0194078407810.3390/jcm9124078Prognostic Value of Troponin Elevation in COVID-19 Hospitalized PatientsElena-Mihaela Cordeanu0Nicolas Duthil1Francois Severac2Hélène Lambach3Jonathan Tousch4Lucas Jambert5Corina Mirea6Alexandre Delatte7Waël Younes8Anne-Sophie Frantz9Hamid Merdji10Valérie Schini-Kerth11Pascal Bilbault12Patrick Ohlmann13Emmanuel Andres14Dominique Stephan15Department of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceDivision of Public Health, Methodology and Biostatistics, University Hospitals of Strasbourg, 67091 Strasbourg, FranceDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceDepartment of Vascular Medicine, Mulhouse Regional Hospital, 68100 Mulhouse, FranceDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceDepartment of Cardiology, Haguenau Regional Hospital, 67500 Haguenau, FranceDepartment of Vascular Medicine, Colmar Regional Hospital, 68000 Colmar, FranceDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceIntensive Care and Reanimation Department, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceUMR 1260 INSERM Regenerative Nanomedecine, Faculty of Pharmacy, Strasbourg University, 67400 Illkirch, FranceEmergency Department, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceCardiology Department, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceInternal Medicine Department, Strasbourg Regional University Hospital, 67091 Strasbourg, FranceDepartment of Hypertension, Vascular Disease and Clinical Pharmacology, Strasbourg Regional University Hospital, 67091 Strasbourg, France(1) Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) penetrates the respiratory epithelium through angiotensin-converting enzyme-2 (ACE2) binding. Myocardial and endothelial expression of ACE2 could account for the growing body of reported evidence of myocardial injury in severe forms of Human Coronavirus Disease 2019 (COVID-19). We aimed to provide insight into the impact of troponin (hsTnI) elevation on SARS-CoV-2 outcomes in patients hospitalized for COVID-19. (2) Methods: This was a retrospective analysis of hospitalized adult patients with the SARS-CoV-2 infection admitted to a university hospital in France. The observation period ended at hospital discharge. (3) Results: During the study period, 772 adult, symptomatic COVID-19 patients were hospitalized for more than 24 h in our institution, of whom 375 had a hsTnI measurement and were included in this analysis. The median age was 66 (55–74) years, and there were 67% of men. Overall, 205 (55%) patients were placed under mechanical ventilation and 90 (24%) died. A rise in hsTnI was noted in 34% of the cohort, whereas only three patients had acute coronary syndrome (ACS) and one case of myocarditis. Death occurred more frequently in patients with hsTnI elevation (HR 3.95, 95% CI 2.69–5.71). In the multivariate regression model, a rise in hsTnI was independently associated with mortality (OR 3.12, 95% CI 1.49–6.65) as well as age ≥ 65 years old (OR 3.17, 95% CI 1.45–7.18) and CRP ≥ 100 mg/L (OR 3.62, 95% CI 1.12–13.98). After performing a sensitivity analysis for the missing values of hsTnI, troponin elevation remained independently and significantly associated with death (OR 3.84, 95% CI 1.78–8.28). (4) Conclusion: Our study showed a four-fold increased risk of death in the case of a rise in hsTnI, underlining the prognostic value of troponin assessment in the COVID-19 context.https://www.mdpi.com/2077-0383/9/12/4078COVID-19troponinmyocardial injurySARS-CoV-2cardiovascularbiomarker |